<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01895959</url>
  </required_header>
  <id_info>
    <org_study_id>Ferring-Euflexxa</org_study_id>
    <nct_id>NCT01895959</nct_id>
  </id_info>
  <brief_title>To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection</brief_title>
  <official_title>Quantifications of Biochemical Changes of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection Using Novel MRI (Magnetic Resonance Imaging) and NMR (Nuclear Magnetic Resonance) Techniques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to identify novel imaging markers for characterizing the&#xD;
      biochemical profiles in synovial fluid and cartilage matrix in OA knee joints after&#xD;
      intra-articular HA (Euflexxa) injection using high field NMR and MRI techniques.&#xD;
&#xD;
      We hypothesize that:&#xD;
&#xD;
        1. High-field HRMAS NMR spectroscopy will provide sensitive measures for biochemical&#xD;
           changes within knee synovial fluid after HA injection;&#xD;
&#xD;
        2. Baseline HRMAS spectroscopy, in particular N-acetyl peaks, as well as early changes of&#xD;
           glutamate will predict patient response of pain relief after HA injection;&#xD;
&#xD;
        3. MR cartilage T1p and T2 quantifications will provide sensitive measures for biochemical&#xD;
           changes within knee cartilage matrix after HA injection. Specifically cartilage T1p and&#xD;
           T2 will decrease in patients who respond to the treatment, indicating potential&#xD;
           beneficial effects of HA injection to cartilage preservation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Identify Imaging Markers for Characterizing the Biochemical Profiles in Synovial Fluid and Cartilage in Knee OA After HA Injection</measure>
    <time_frame>3 months</time_frame>
    <description>The study will demonstrate the feasibility of using MRI and NMR techniques to quantify biochemical changes in synovial fluid and cartilage matrix in OA knees after HA injection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Quantify Synovial Fluid Biochemical Changes Using High Field HRMAS NMR Spectroscopy</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>To Quantify Cartilage Matrix Changes Using MR T1p ad T2 Mapping at 3T MRI</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Euflexxa</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>EUFLEXXAÂ® is a hyaluronate hydrogel produced from bacteria, in a phosphate-buffered saline solution. It is given as a three week treatment regimen. It involves injecting of 2cc or 20mg intra-articularly once per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Euflexxa</intervention_name>
    <description>Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.</description>
    <arm_group_label>Euflexxa</arm_group_label>
    <other_name>hyaluronic acid injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Imaging (MRI)</intervention_name>
    <description>MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).</description>
    <arm_group_label>Euflexxa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 80 years&#xD;
&#xD;
          -  Symptomatic knee OA as defined by the American College of Rheumatology criteria&#xD;
&#xD;
          -  Kellgren-Lawrence grade I, II or III on prior x-rays (take within 6 months of&#xD;
             screening visit)&#xD;
&#xD;
          -  knee pain score &gt;40 mm on a 100 mm visual analogue scale for &gt; 15 days in the last&#xD;
             month&#xD;
&#xD;
          -  NSAIDs permitted if the dose has been stable for at least one month prior to baseline&#xD;
             and stays stable during the study&#xD;
&#xD;
          -  Have been recommended for Euflexxa treatment by physician&#xD;
&#xD;
          -  Knee effusion based on clinical exam or imaging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contraindication to MRI (pregnancy, metallic fragments in the eyes, vascular&#xD;
             clips, Pacemakers etc)&#xD;
&#xD;
          -  History of knee replacement&#xD;
&#xD;
          -  Known sensitivity or allergy to any component of Euflexxa&#xD;
&#xD;
          -  Inflammatory arthritis&#xD;
&#xD;
          -  Previously received viscosupplementation therapy within 6 months of study enrollment&#xD;
&#xD;
          -  Intra-articular injection of corticosteroid to study joint within the past 3 months&#xD;
&#xD;
          -  Arthroscopic or open surgery within the previous 12 months or planned surgery to the&#xD;
             study joint&#xD;
&#xD;
          -  Concomitant medications of oral/parenteral corticosteroids&#xD;
&#xD;
          -  Morbid obesity defined as body mass index (BMI) &gt;40 kg/m2&#xD;
&#xD;
          -  Active malignancy; an active systemic infection; recent high impact or high energy&#xD;
             trauma (clinically defined) to the study joint&#xD;
&#xD;
          -  Large knee effusion based on clinical exam or imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaojuan Li, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF - China Basin Imaging Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 5, 2013</study_first_submitted>
  <study_first_submitted_qc>July 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <results_first_submitted>October 26, 2020</results_first_submitted>
  <results_first_submitted_qc>October 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2020</results_first_posted>
  <last_update_submitted>October 26, 2020</last_update_submitted>
  <last_update_submitted_qc>October 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>knee osteoarthritis (OA)</keyword>
  <keyword>hyaluronic acid injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>Subjects treated with Euflexxa</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>Subjects treated with Euflexxa</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.17" spread="9.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Identify Imaging Markers for Characterizing the Biochemical Profiles in Synovial Fluid and Cartilage in Knee OA After HA Injection</title>
        <description>The study will demonstrate the feasibility of using MRI and NMR techniques to quantify biochemical changes in synovial fluid and cartilage matrix in OA knees after HA injection.</description>
        <time_frame>3 months</time_frame>
        <population>The PI left institution and all efforts to locate outcome measure data have been exhausted and therefore cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Subjects treated with Euflexxa</description>
          </group>
        </group_list>
        <measure>
          <title>To Identify Imaging Markers for Characterizing the Biochemical Profiles in Synovial Fluid and Cartilage in Knee OA After HA Injection</title>
          <description>The study will demonstrate the feasibility of using MRI and NMR techniques to quantify biochemical changes in synovial fluid and cartilage matrix in OA knees after HA injection.</description>
          <population>The PI left institution and all efforts to locate outcome measure data have been exhausted and therefore cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Quantify Synovial Fluid Biochemical Changes Using High Field HRMAS NMR Spectroscopy</title>
        <time_frame>3 months</time_frame>
        <population>The PI left institution and all efforts to locate outcome measure data have been exhausted and therefore cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Subjects treated with Euflexxa</description>
          </group>
        </group_list>
        <measure>
          <title>To Quantify Synovial Fluid Biochemical Changes Using High Field HRMAS NMR Spectroscopy</title>
          <population>The PI left institution and all efforts to locate outcome measure data have been exhausted and therefore cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>To Quantify Cartilage Matrix Changes Using MR T1p ad T2 Mapping at 3T MRI</title>
        <time_frame>3 months</time_frame>
        <population>The PI left institution and all efforts to locate outcome measure data have been exhausted and therefore cannot be reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Subjects treated with Euflexxa</description>
          </group>
        </group_list>
        <measure>
          <title>To Quantify Cartilage Matrix Changes Using MR T1p ad T2 Mapping at 3T MRI</title>
          <population>The PI left institution and all efforts to locate outcome measure data have been exhausted and therefore cannot be reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>Subjects treated with Euflexxa</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>knee pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Xiaojuan Li, PhD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-353-4909</phone>
      <email>Xiaojuan.li@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

